Evidence map›Paper›PMID 40624120›Full record

Trial reportProstate cancer and prostatic diseases2026

Thulium fiber laser versus holmium MOSES

Hazem Elmansy, Saud Alhelal, Oksana Blahitko, Ryan Kelly, Amr Hodhod, Ruba Abdul Hadi, Husain Alaradi, Khaled Alotaibi, Ahmed Mousa, Ahmed S Zakaria

Abstract readRandomized Controlled TrialComparative Study
PubMed Publisher
In one paragraph

Trial report in Prostate cancer and prostatic diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Hazem ElmansyDepartment of Urology, Northern Ontario School of Medicine, Thunder Bay Regional Health Sciences Centre, Thunder Bay, ON, Canada. hazem.mansy@rocketmail.com.ORCID http://orcid.org/0000-0003-3601-4626
Saud AlhelalDepartment of Urology, Northern Ontario School of Medicine, Thunder Bay Regional Health Sciences Centre, Thunder Bay, ON, Canada.
Oksana BlahitkoDepartment of Urology, Northern Ontario School of Medicine, Thunder Bay Regional Health Sciences Centre, Thunder Bay, ON, Canada.
Ryan KellyDepartment of Urology, Northern Ontario School of Medicine, Thunder Bay Regional Health Sciences Centre, Thunder Bay, ON, Canada.
Amr HodhodDepartment of Urology, King Abdulaziz Medical City, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia.
Ruba Abdul HadiDepartment of Urology, Northern Ontario School of Medicine, Thunder Bay Regional Health Sciences Centre, Thunder Bay, ON, Canada.
Husain AlaradiDepartment of Urology, Northern Ontario School of Medicine, Thunder Bay Regional Health Sciences Centre, Thunder Bay, ON, Canada.ORCID http://orcid.org/0000-0002-7004-4741
Khaled AlotaibiDepartment of Urology, Northern Ontario School of Medicine, Thunder Bay Regional Health Sciences Centre, Thunder Bay, ON, Canada.ORCID http://orcid.org/0009-0003-6337-2645
Ahmed MousaDepartment of Urology, Northern Ontario School of Medicine, Thunder Bay Regional Health Sciences Centre, Thunder Bay, ON, Canada.
Ahmed S ZakariaDepartment of Urology, Northern Ontario School of Medicine, Thunder Bay Regional Health Sciences Centre, Thunder Bay, ON, Canada.ORCID http://orcid.org/0000-0002-4582-9969

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWe aimed to compare intraoperative and one-year postoperative outcomes of patients treated for benign prostatic hyperplasia (BPH) with holmium laser enucleation of the prostate using MOSES

methodsWe included 104 patients who underwent M-HoLEP or ThuFLEP between June 2022 and January 2024 in this randomized controlled trial. Patients' preoperative and prostate data were evaluated. Intraoperative data and perioperative outcomes were analyzed over the 12-month follow-up period.

resultsFifty-two patients underwent M-HoLEP, and 52 were managed with ThuFLEP. There were no statistically significant differences in the preoperative characteristics between the groups. M-HoLEP had a shorter median enucleation time (50 vs. 57.5 minutes, p < 0.001) and demonstrated significantly higher enucleation efficiency than ThuFLEP (1.97 vs. 1.49 g/min, p < 0.001). Significant differences were observed favoring M-HoLEP regarding continuous bladder irrigation time, hematuria scale, duration of postoperative hematuria, catheterization time, and hospital stay. Approximately 30.8% of ThuFLEP patients were admitted with immediate postoperative hematuria versus 7.7% in the M-HoLEP group, p = 0.003). The postoperative outcomes were comparable between the cohorts up to 12 months.

conclusionsThulium fiber laser (TFL) and MOSES

Indexed as

Lasers, Solid-StateLaser TherapyProstatectomyProstatic HyperplasiaThuliumAgedFollow-Up StudiesHumansMaleMiddle AgedProspective StudiesTreatment OutcomeThulium

Identifiers

PMID40624120

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.